These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 27517841)

  • 1. Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment.
    Yoon SH; Kim YH; Lee YJ; Park J; Kim JW; Lee HS; Kim B
    PLoS One; 2016; 11(8):e0161278. PubMed ID: 27517841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of volume-based parameters using
    Park JS; Lee N; Beom SH; Kim HS; Lee CK; Rha SY; Chung HC; Yun M; Cho A; Jung M
    Gastric Cancer; 2018 Mar; 21(2):213-224. PubMed ID: 28643145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.
    Gomez-Martin C; Plaza JC; Pazo-Cid R; Salud A; Pons F; Fonseca P; Leon A; Alsina M; Visa L; Rivera F; Galan MC; Del Valle E; Vilardell F; Iglesias M; Fernandez S; Landolfi S; Cuatrecasas M; Mayorga M; Jose Paulés M; Sanz-Moncasi P; Montagut C; Garralda E; Rojo F; Hidalgo M; Lopez-Rios F
    J Clin Oncol; 2013 Dec; 31(35):4445-52. PubMed ID: 24127447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy.
    Kadowaki S; Masuishi T; Eto T; Narita Y; Taniguchi H; Ura T; Ando M; Tajika M; Niwa Y; Yatabe Y; Muro K
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):807-813. PubMed ID: 28821938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation.
    Qiu MZ; Li Q; Wang ZQ; Liu TS; Liu Q; Wei XL; Jin Y; Wang DS; Ren C; Bai L; Zhang DS; Wang FH; Li YH; Xu RH
    Int J Cancer; 2014 May; 134(10):2468-77. PubMed ID: 24155030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3).
    Seo S; Ryu MH; Park YS; Ahn JY; Park Y; Park SR; Ryoo BY; Lee GH; Jung HY; Kang YK
    Gastric Cancer; 2019 May; 22(3):527-535. PubMed ID: 30386954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type.
    Xu C; Liu Y; Jiang D; Li Q; Ge X; Zhang Y; Huang J; Su J; Ji Y; Hou J; Lu S; Hou Y; Liu T
    Oncotarget; 2017 May; 8(20):33185-33196. PubMed ID: 28388541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of primary colorectal cancer heterogeneity by using whole-tumor texture analysis: contrast-enhanced CT texture as a biomarker of 5-year survival.
    Ng F; Ganeshan B; Kozarski R; Miles KA; Goh V
    Radiology; 2013 Jan; 266(1):177-84. PubMed ID: 23151829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer.
    Cho JH; Lim JY; Cho JY
    World J Gastroenterol; 2017 Nov; 23(41):7407-7414. PubMed ID: 29151694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship Between 18F-FDG PET/CT Findings and HER2 Expression in Gastric Cancer.
    Chen R; Zhou X; Liu J; Huang G
    J Nucl Med; 2016 Jul; 57(7):1040-4. PubMed ID: 26966162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer.
    Wakatsuki T; Yamamoto N; Sano T; Chin K; Kawachi H; Takahari D; Ogura M; Ichimura T; Nakayama I; Osumi H; Matsushima T; Suenaga M; Shinozaki E; Hiki N; Ishikawa Y; Yamaguchi K
    J Gastroenterol; 2018 Nov; 53(11):1186-1195. PubMed ID: 29633013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer.
    Takahashi N; Furuta K; Taniguchi H; Sasaki Y; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Hamaguchi T; Shimada Y; Yamada Y
    Oncotarget; 2016 Jan; 7(4):4925-38. PubMed ID: 26716644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes.
    Xuan Q; Ji H; Tao X; Xu Y; Zhang Q
    Breast Cancer Res Treat; 2015 Apr; 150(3):581-8. PubMed ID: 25762478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.
    Kataoka H; Mori Y; Shimura T; Nishie H; Natsume M; Mochizuki H; Hirata Y; Sobue S; Mizushima T; Sano H; Mizuno Y; Nakamura M; Hirano A; Tsuchida K; Adachi K; Seno K; Kitagawa M; Kawai T; Joh T
    Cancer Chemother Pharmacol; 2016 May; 77(5):957-62. PubMed ID: 27002325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab.
    Lee HJ; Kim JY; Park SY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
    Am J Clin Pathol; 2015 Oct; 144(4):570-8. PubMed ID: 26386078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathologic Response of HER2-positive Gastric Cancer to Trastuzumab-based Chemotherapy.
    Urabe M; Ushiku T; Seto Y; Fukayama M
    Am J Surg Pathol; 2016 Oct; 40(10):1326-33. PubMed ID: 27259008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visceral and subcutaneous fat as new independent predictive factors of survival in locally advanced gastric carcinoma patients treated with neo-adjuvant chemotherapy.
    Li XT; Tang L; Chen Y; Li YL; Zhang XP; Sun YS
    J Cancer Res Clin Oncol; 2015 Jul; 141(7):1237-47. PubMed ID: 25537963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypovascular pancreas head adenocarcinoma: CT texture analysis for assessment of resection margin status and high-risk features.
    Kulkarni A; Carrion-Martinez I; Jiang NN; Puttagunta S; Ruo L; Meyers BM; Aziz T; van der Pol CB
    Eur Radiol; 2020 May; 30(5):2853-2860. PubMed ID: 31953662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer.
    Yagi S; Wakatsuki T; Yamamoto N; Chin K; Takahari D; Ogura M; Ichimura T; Nakayama I; Osumi H; Shinozaki E; Suenaga M; Fujisaki J; Ishikawa Y; Yamaguchi K; Namikawa K; Horiuchi Y
    Gastric Cancer; 2019 May; 22(3):518-525. PubMed ID: 30328533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.